hsa-mir-4299: Hsa-mir-4299 is a non-intragenic miRNA transcribed from chr11 [PMC4619470]. In Parkinson's disease (PD) patients, hsa-mir-4299 did not show any significant differences compared to controls [PMC4619470]. However, a significant down-regulation of hsa-mir-4299 in plasma was observed, suggesting its potential role in disease deterioration [PMC4619470]. Hsa-mir-4299 is predicted to down-regulate EPHA4, possibly as a compensating mechanism for neuronal death [PMC4619470]. In amyotrophic lateral sclerosis (ALS) patients, hsa-mir-4299 was significantly down-regulated in plasma [PMC4619470]. Hsa-miR-4649-5p and hsa-mir-4299 showed high area under the curve (AUC) values and have the potential to be ALS diagnosis biomarkers [PMC4619470]. Hsa-miR-4649-5p and hsa-mir-4299 have commonly predicted target genes, with EPHA4 being the most notable target gene according to miRmap analysis [PMC4619470]. In ALS patients' motor cortex samples, hsa-mir-4299 was notably up-regulated [PMC4619470]. Hsa-miR-4649-5p and hsa-mir-4299 were also found to be dysregulated in other diseases such as CHIKV infection and acute myocardial infarction (AMI) [PMC9967650] [PMC7206869]. The expression of hsa-miR-4649-p and hsa-mir 42999 were found to be correlated with disease progression in ALS patients and may serve as prognostic biomarkers [PMC6002137].